Bristol-Myers Squibb earnings beat by $0.09, revenue topped estimates

Investing.com - Bristol-Myers Squibb (NYSE: BMY) reported fourth quarter EPS of $1.82, $0.09 better than the analyst estimate of $1.73. Revenue for the quarter came in at $11.4B versus the consensus estimate of $11.21B.
Guidance
Bristol-Myers Squibb sees FY 2023 EPS of $7.95-$8.25 versus the analyst consensus of $8.00.
Bristol-Myers Squibb's stock price closed at $71.23. It is down -9.58% in the last 3 months and up 11.18% in the last 12 months.
Bristol-Myers Squibb saw 7 positive EPS revisions and 6 negative EPS revisions in the last 90 days. See Bristol-Myers Squibb's stock price’s past reactions to earnings here.
According to InvestingPro, Bristol-Myers Squibb's Financial Health score is "great performance".
Check out Bristol-Myers Squibb's recent earnings performance , and Bristol-Myers Squibb's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb
Drop an image here or